Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 634

1.

Evaluation of Bleeding Events Requiring Hospitalization in Patients With Atrial Fibrillation Receiving Dabigatran, Warfarin, or Antiplatelet Therapy.

Riley TR, Gauthier-Lewis ML, Sanchez CK, Riley TT.

J Pharm Pract. 2016 Mar 7. pii: 0897190016630408. [Epub ahead of print]

PMID:
26951615
2.

Historical Hallmarks of Anticoagulation and Antiplatelet Agents.

Tsoucalas G, Chevallier J, Karamanou M, Papaioannou T, Sgantzos M, Androutsos G.

Curr Pharm Des. 2016;22(13):1857-61.

PMID:
26750139
3.

ATRIAL FIBRILLATION AND STROKE PREVENTION PRACTICES IN PATIENTS WITH CANDIDACY FOR ANTICOAGULATION THERAPY.

Ullah I, Ahmad F, Ahmad S, Hayat Y.

J Ayub Med Coll Abbottabad. 2015 Jul-Sep;27(3):669-72.

PMID:
26721036
4.

Stroke Event Rates and the Optimal Antithrombotic Choice of Patients With Paroxysmal Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Chen Y, Zhao Y, Dang G, Ouyang F, Chen X, Zeng J.

Medicine (Baltimore). 2015 Dec;94(52):e2364. doi: 10.1097/MD.0000000000002364.

5.

Preventing Thrombosis to Improve Outcomes in Heart Failure Patients.

Shantsila E, Lip GY.

Prog Cardiovasc Dis. 2016 Jan-Feb;58(4):386-92. doi: 10.1016/j.pcad.2015.09.005. Epub 2015 Oct 1. Review.

PMID:
26433062
6.

Non-VKA Oral Anticoagulants and Antiplatelet Therapy for Stroke Prevention in Patients with Atrial Fibrillation: a Meta-analysis of Randomized Controlled Trials.

Kumar S, Danik SB, Altman RK, Barrett CD, Lip GY, Chatterjee S, Roubin GS, Natale A, Danik JS.

Cardiol Rev. 2015 Aug 11. [Epub ahead of print]

PMID:
26274538
7.

Net Clinical Benefit for Oral Anticoagulation, Aspirin, or No Therapy in Nonvalvular Atrial Fibrillation Patients With 1 Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex).

Lip GY, Skjøth F, Rasmussen LH, Nielsen PB, Larsen TB.

J Am Coll Cardiol. 2015 Jul 28;66(4):488-90. doi: 10.1016/j.jacc.2015.05.044. No abstract available.

PMID:
26205604
8.

Non-vitamin K antagonist oral anticoagulants: new choices for patient management in atrial fibrillation.

Saliba W.

Am J Cardiovasc Drugs. 2015 Oct;15(5):323-35. doi: 10.1007/s40256-015-0124-5. Review.

9.

New oral anticoagulant and antiplatelet agents for neurosurgeons.

Kimpton G, Dabbous B, Leach P.

Br J Neurosurg. 2015;29(5):614-21. doi: 10.3109/02688697.2015.1029433. Epub 2015 Jun 3.

PMID:
26037940
10.

Activated Hemostatic Biomarkers in Patients with Implanted Left Ventricle Assist Devices: Are Heparin and/or Clopidogrel Justified?

Pacholewicz J, Kuliczkowski W, Kaczmarski J, Zakliczyński M, Garbacz M, Zembala M, Serebruany V.

Cardiology. 2015;131(3):172-6. doi: 10.1159/000375232. Epub 2015 May 6.

PMID:
25967953
11.

Risk of bleeding and stroke with oral anticoagulation and antiplatelet therapy in patients with atrial fibrillation in Taiwan: a nationwide cohort study.

Chen PC, Lip GY, Yeh G, Lin HJ, Chien KL.

PLoS One. 2015 Apr 29;10(4):e0125257. doi: 10.1371/journal.pone.0125257. eCollection 2015.

12.

Effects of anticoagulants on outcome of femoral neck fracture surgery.

Ginsel BL, Taher A, Whitehouse SL, Bell JJ, Pulle CR, Crawford RW.

J Orthop Surg (Hong Kong). 2015 Apr;23(1):29-32.

13.

Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics.

Beitelshees AL, Voora D, Lewis JP.

Pharmgenomics Pers Med. 2015 Feb 9;8:43-61. doi: 10.2147/PGPM.S52900. eCollection 2015. Review.

14.

Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm: Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial substudy.

Homma S, Thompson JL, Qian M, Ye S, Di Tullio MR, Lip GY, Mann DL, Sacco RL, Levin B, Pullicino PM, Freudenberger RS, Teerlink JR, Graham S, Mohr JP, Labovitz AJ, Buchsbaum R, Estol CJ, Lok DJ, Ponikowski P, Anker SD; WARCEF Investigators.

Circ Heart Fail. 2015 May;8(3):504-9. doi: 10.1161/CIRCHEARTFAILURE.114.001725. Epub 2015 Apr 7.

PMID:
25850425
15.

Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score.

Lip GY, Skjøth F, Rasmussen LH, Larsen TB.

J Am Coll Cardiol. 2015 Apr 14;65(14):1385-94. doi: 10.1016/j.jacc.2015.01.044. Epub 2015 Mar 11.

16.

Safety and efficacy of antiplatelet/anticoagulation regimens after Viabahn stent graft treatment for femoropopliteal occlusive disease.

Ullery BW, Tran K, Itoga N, Casey K, Dalman RL, Lee JT.

J Vasc Surg. 2015 Jun;61(6):1479-88. doi: 10.1016/j.jvs.2014.12.062. Epub 2015 Feb 19.

PMID:
25704407
17.

ACP Journal Club: after initial anticoagulation for a first unprovoked venous thromboembolism, aspirin reduced recurrence.

Dunn A.

Ann Intern Med. 2015 Feb 17;162(4):JC5. doi: 10.7326/ACPJC-2015-162-4-005. No abstract available.

PMID:
25686192
18.

Response to letter regarding article, "Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control".

Chan PH, Hai JJ, Siu CW.

Stroke. 2015 Mar;46(3):e72. doi: 10.1161/STROKEAHA.114.008581. Epub 2015 Feb 3. No abstract available.

19.

Letter by Feng et al regarding article, "Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control".

Feng X, Huan Y, Lv Y.

Stroke. 2015 Mar;46(3):e71. doi: 10.1161/STROKEAHA.114.008578. Epub 2015 Feb 3. No abstract available.

20.

Efficacy and safety of oral anticoagulants versus aspirin for patients with atrial fibrillation: a meta-analysis.

Zhang JT, Chen KP, Zhang S.

Medicine (Baltimore). 2015 Jan;94(4):e409. doi: 10.1097/MD.0000000000000409. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk